1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Systems Biology In CNS: Mixed Results For IRLAB's Dyskinesia Candidate

 
• By John Davis

A novel systems biology/network pharmacology approach to drug discovery in Parkinson’s disease is encouraging despite puzzling divergence in efficacy measures.  

Parkinsons
Daily tasks can become difficult in advanced Parkinson's disease • Source: Shutterstock.

IRLAB Therapeutics AB’s lead neurological, IRL790, had no effect on the primary efficacy variable in a Phase IIa study in Parkinson’s patients, a finding linked to a sharp decline in the Swedish biotech’s share price on 16 July when top-line results from the study were announced, even though two other pre-specified efficacy measures showed beneficial effects.

“It is clear the drug is anti-dyskinetic in two of the measures,” said Nicholas Waters, CEO of IRLAB, who said he was puzzled by the differences between the efficacy measures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

More from Therapy Areas